
    
      This is a double-blind, placebo-controlled, parallel group study in pediatric subjects who
      have persistent attention impairment following treatment for cancer. This trial has three
      phases: (1) pre-randomization to establish eligibility, (2) a 12-week, double-blind,
      placebo-controlled, parallel-group phase with dose escalation based on body weight, (3) a
      12-week, blinded extension phase during which all subjects will receive active drug.
    
  